Alumis
Price & Volume
Stats
See more52W Range | $2.76-$30.60 |
Market Cap | $2.9B |
Shares Short | 12M |
Financials
See moreRevenue (12 Mos) | $24M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $24M |
Diluted EPS | -$2.86 |
News
See moreYahoo Finance • 30 days ago
Commit To Buy Alumis At $15, Earn 34.6% Annualized Using Options
Yahoo Finance • last month
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
Yahoo Finance • last month
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Yahoo Finance • 2 months ago
Alumis to Present at the Leerink Partners Global Healthcare Conference
About
CEO | Mr. Martin Babler Ph.D. |
Address | 280 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 221 |